Nicola Baker-Munton
Amministratore Delegato presso Stratagem Intellectual Property Management Ltd.
Profilo
Nicola Baker-Munton is the founder of Stratagem IPM, which was founded in 1999.
He is currently the CEO of Stratagem Intellectual Property Management Ltd.
and a Non-Executive Director at Cypralis Ltd.
Posizioni attive di Nicola Baker-Munton
| Società | Posizione | Inizio |
|---|---|---|
Cypralis Ltd.
 Cypralis Ltd. BiotechnologyHealth Technology Cypralis Ltd. provides novel medicines for degenerative diseases. The firm focuses on discovery of novel therapeutics based on modulation of peptidyl-prolyl isomerases. The company was founded in 2013 and is headquartered in Ongar, the United Kingdom. | Direttore/Membro del Consiglio | - |
Stratagem Intellectual Property Management Ltd.
 Stratagem Intellectual Property Management Ltd. Miscellaneous Commercial ServicesCommercial Services Stratagem Intellectual Property Management Ltd. manages patent and copyright agencies. The private company is based in Cambridge, UK. The British company was founded in 1999. The CEO is Nicola Baker-Munton. | Amministratore Delegato | - |
Precedenti posizioni note di Nicola Baker-Munton
| Società | Posizione | Fine |
|---|---|---|
| Stratagem IPM | Fondatore | - |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 3 |
|---|---|
| Stratagem IPM | |
Stratagem Intellectual Property Management Ltd.
Stratagem Intellectual Property Management Ltd. Miscellaneous Commercial ServicesCommercial Services Stratagem Intellectual Property Management Ltd. manages patent and copyright agencies. The private company is based in Cambridge, UK. The British company was founded in 1999. The CEO is Nicola Baker-Munton. | Commercial Services |
Cypralis Ltd.
Cypralis Ltd. BiotechnologyHealth Technology Cypralis Ltd. provides novel medicines for degenerative diseases. The firm focuses on discovery of novel therapeutics based on modulation of peptidyl-prolyl isomerases. The company was founded in 2013 and is headquartered in Ongar, the United Kingdom. | Health Technology |
- Borsa valori
- Insiders
- Nicola Baker-Munton
